NIOX Group Updates Total Voting Rights Following Share Option Exercises

Circassia Pharmaceuticals ( (GB:NIOX) ) has shared an announcement.

NIOX Group plc, a company listed on AIM, has announced an update regarding its total voting rights. As of May 31, 2025, the company has 417,417,579 Ordinary Shares in issue, each carrying one voting right, with no shares held in treasury. Recent exercises of employee share options have resulted in the issuance of 735,050 new Ordinary Shares, which have been admitted via block listing and rank equally with existing shares. This update is relevant for shareholders calculating their interest in the company under FCA’s rules.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Spark’s Take on GB:NIOX Stock

According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.

Circassia Pharmaceuticals scores well on financial performance due to strong revenue growth and cash flow management. Technical analysis and valuation indicate some caution with potential overvaluation. Corporate events suggest strategic growth but also highlight risks from the economic environment. Overall, the stock presents a balanced investment profile with both strengths and concerns.

To see Spark’s full report on GB:NIOX stock, click here.

More about Circassia Pharmaceuticals

Average Trading Volume: 1,783,213

Technical Sentiment Signal: Strong Buy

Current Market Cap: £278.3M

For an in-depth examination of NIOX stock, go to TipRanks’ Stock Analysis page.